Up next
Author

Key View

  • India’s production-linked incentive scheme will reduce imports by promoting domestic manufacturing of pharmaceuticals.
  • The country will remain keen to secure its drugs market from external shocks, lessen import dependencies, and continue support for the domestic production capabilities in APIs.
  • Reducing India’s dependence on Mainland China will not be easy to achieve.

India’s production-linked incentive (PLI) scheme will reduce import by promoting domestic manufacturing of pharmaceuticals. The Indian government approved a production-linked incentive (PLI) scheme in February 2021 targeting India’s pharmaceutical sector for enhancing drug manufacturing capabilities and expanding exports. The key objectives of the scheme are:

Read More

You May Also Like
Modi To Lead India Again, But Reforms To Remain Gradual

Modi To Lead India Again, But Reforms To Remain Gradual

Key View We expect PM Modi and the Bharatiya Janata Party to…
SCB EIC expects a slower growth momentum for Thai economy, underweighting recovery in 2024.

SCB EIC expects a slower growth momentum for Thai economy, underweighting recovery in 2024.

Despite a modest 1.7% year-on-year growth in Q4/2023, the Thai economy struggled with challenges such as a decline in public consumption and investment. SCB EIC anticipates higher growth in Q1/2024, driven by robust private consumption and a resurgence in exports. However, a slow recovery is expected in 2024 due to various risks and limited public spending support.
SCB EIC anticipates that the MPC still has room to lower the policy rate again next year.

SCB EIC anticipates that the MPC still has room to lower the policy rate again next year.

The MPC maintained the policy rate at 2.25%, aligning with SCB EIC’s projections. Economic challenges are expected to increase due to global competition and uncertainties from major economies. Inflation is projected to return to the target range. The MPC shows limited concern over credit growth slowdown.